期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 55, 期 5, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ijantimicag.2020.105938
关键词
COVID-19; SARS-CoV-2; Coronavirus; Chloroquine
资金
- IHU-Mediterranee Infection
- CNRS (Marseille, France)
- Programme d'investissement d'avenir [Mediterranee Infection 10-1AHU-03]
- University of Marseille
Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. In the absence of a known efficient therapy and because of the situation of a public-health emergency, it made sense to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2 since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle. (C) 2020 The Author(s). Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据